BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 8697888)

  • 1. Sparfloxacin therapy for experimental endocarditis caused by methicillin-resistant Staphylococcus aureus.
    Maserati R; Cagni AE; Segú C
    Chemotherapy; 1996; 42(2):133-9. PubMed ID: 8697888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of sparfloxacin, temafloxacin, and ciprofloxacin for prophylaxis and treatment of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.
    Cagni A; Chuard C; Vaudaux PE; Schrenzel J; Lew DP
    Antimicrob Agents Chemother; 1995 Aug; 39(8):1655-60. PubMed ID: 7486895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CI-960, a new fluoroquinolone, for therapy of experimental ciprofloxacin-susceptible and -resistant Staphylococcus aureus endocarditis.
    Kaatz GW; Seo SM; Lamp KC; Bailey EM; Rybak MJ
    Antimicrob Agents Chemother; 1992 Jun; 36(6):1192-7. PubMed ID: 1329613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacies of moxifloxacin, ciprofloxacin, and vancomycin against experimental endocarditis due to methicillin-resistant Staphylococcus aureus expressing various degrees of ciprofloxacin resistance.
    Entenza JM; Que YA; Vouillamoz J; Glauser MP; Moreillon P
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3076-83. PubMed ID: 11600359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral temafloxacin versus vancomycin for therapy of experimental endocarditis caused by methicillin-resistant Staphylococcus aureus.
    Hessen MT; Pitsakis PG; Kaye D
    Antimicrob Agents Chemother; 1990 Jun; 34(6):1143-5. PubMed ID: 2393273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Y-688, a new quinolone active against quinolone-resistant Staphylococcus aureus: lack of in vivo efficacy in experimental endocarditis.
    Entenza JM; Marchetti O; Glauser MP; Moreillon P
    Antimicrob Agents Chemother; 1998 Aug; 42(8):1889-94. PubMed ID: 9687379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levofloxacin versus ciprofloxacin, flucloxacillin, or vancomycin for treatment of experimental endocarditis due to methicillin-susceptible or -resistant Staphylococcus aureus.
    Entenza JM; Vouillamoz J; Glauser MP; Moreillon P
    Antimicrob Agents Chemother; 1997 Aug; 41(8):1662-7. PubMed ID: 9257737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of linezolid in treatment of experimental endocarditis caused by methicillin-resistant Staphylococcus aureus.
    Dailey CF; Dileto-Fang CL; Buchanan LV; Oramas-Shirey MP; Batts DH; Ford CW; Gibson JK
    Antimicrob Agents Chemother; 2001 Aug; 45(8):2304-8. PubMed ID: 11451689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parenteral sparfloxacin compared with ceftriaxone in treatment of experimental endocarditis due to penicillin-susceptible and -resistant streptococci.
    Entenza JM; Blatter M; Glauser MP; Moreillon P
    Antimicrob Agents Chemother; 1994 Dec; 38(12):2683-8. PubMed ID: 7695248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic effect of ME1036 on endocarditis experimentally induced by methicillin-resistant Staphylococcus aureus.
    Nagura J; Kijima K; Kurazono M; Takahata S; Sugano T; Tanaka Y; Hirai Y; Yamada K; Takayama Y; Shitara E; Yonezawa M
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3526-8. PubMed ID: 16048975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of sparfloxacin and autoradiographic diffusion pattern of [14C]Sparfloxacin in experimental Staphylococcus aureus joint prosthesis infection.
    Crémieux AC; Mghir AS; Bleton R; Manteau M; Belmatoug N; Massias L; Garry L; Sales N; Mazière B; Carbon C
    Antimicrob Agents Chemother; 1996 Sep; 40(9):2111-6. PubMed ID: 8878590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of trovafloxacin against experimental Staphylococcus aureus endocarditis.
    Kaatz GW; Seo SM; Aeschlimann JR; Houlihan HH; Mercier RC; Rybak MJ
    Antimicrob Agents Chemother; 1998 Feb; 42(2):254-6. PubMed ID: 9527768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enoxacin compared with vancomycin for the treatment of experimental methicillin-resistant Staphylococcus aureus endocarditis.
    Gilbert M; Boscia JA; Kobasa WD; Kaye D
    Antimicrob Agents Chemother; 1986 Mar; 29(3):461-3. PubMed ID: 3459391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vancomycin or vancomycin plus netilmicin for methicillin- and gentamicin-resistant Staphylococcus aureus aortic valve experimental endocarditis.
    Perdikaris G; Giamarellou H; Pefanis A; Donta I; Karayiannakos P
    Antimicrob Agents Chemother; 1995 Oct; 39(10):2289-94. PubMed ID: 8619584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of garenoxacin in treatment of experimental endocarditis due to Staphylococcus aureus or viridans group streptococci.
    Entenza JM; Vouillamoz J; Glauser MP; Moreillon P
    Antimicrob Agents Chemother; 2004 Jan; 48(1):86-92. PubMed ID: 14693523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of Telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus.
    Madrigal AG; Basuino L; Chambers HF
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3163-5. PubMed ID: 16048918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus.
    Chambers HF
    Antimicrob Agents Chemother; 2005 Mar; 49(3):884-8. PubMed ID: 15728879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative efficacy of trovafloxacin in experimental endocarditis caused by ciprofloxacin-sensitive, methicillin-resistant Staphylococcus aureus.
    Kim YS; Liu Q; Chow LL; Chambers HF; Täuber MG
    Antimicrob Agents Chemother; 1998 Dec; 42(12):3325-7. PubMed ID: 9835540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of levofloxacin for experimental aortic-valve endocarditis in rabbits infected with viridans group streptococcus or Staphylococcus aureus.
    Chambers HF; Xiang Q; Liu ; Chow LL; Hackbarth C
    Antimicrob Agents Chemother; 1999 Nov; 43(11):2742-6. PubMed ID: 10543757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of resistance to fleroxacin during therapy of experimental methicillin-susceptible Staphylococcus aureus endocarditis.
    Kaatz GW; Seo SM; Barriere SL; Albrecht LM; Rybak MJ
    Antimicrob Agents Chemother; 1991 Aug; 35(8):1547-50. PubMed ID: 1929325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.